【2h】

Patient Registries in Idiopathic Pulmonary Fibrosis

机译:特发性肺纤维化患者注册

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established. These registries are collecting a wealth of longitudinal data on thousands of patients with this rare disease. The data collected in these registries will be complementary to data collected in clinical trials because the patient populations studied in registries have a broader spectrum of disease severity and comorbidities and can be followed for a longer period of time. Maintaining the quality and completeness of registry databases presents administrative and resourcing challenges, but it is important to ensuring the robustness of the analyses. Data from patient registries have already helped improve understanding of the clinical characteristics of patients with IPF, the impact that the disease has on their quality of life and survival, and current practices in diagnosis and management. In the future, analyses of biospecimens linked to detailed patient profiles will provide the opportunity to identify biomarkers linked to disease progression, facilitating the development of precision medicine approaches for prognosis and therapy in patients with IPF.
机译:在过去的十年中,已经建立了几个大型的特发性肺纤维化(IPF)患者注册中心。这些注册表正在收集有关数千种这种罕见疾病患者的大量纵向数据。这些注册管理机构收集的数据将补充临床试验中收集的数据,因为在注册管理机构中研究的患者人群的疾病严重程度和合并症范围更广,并且可以随访更长的时间。维护注册表数据库的质量和完整性提出了管理和资源配置方面的挑战,但是对于确保分析的稳定性很重要。来自患者登记处的数据已经帮助增进了对IPF患者临床特征的了解,该疾病对其生活质量和生存的影响以及当前的诊断和管理方法。将来,对与详细患者资料相关的生物标本进行分析将提供机会,以鉴定与疾病进展相关的生物标志物,从而有助于开发用于IPF患者预后和治疗的精确医学方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号